Rochester, NY3 Active Studies

Neuroendocrine Tumors Clinical Trials in Rochester, NY

Find 3 actively recruiting neuroendocrine tumors clinical trials in Rochester, NY. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
2,000,332
Enrolling

Recruiting Neuroendocrine Tumors Studies in Rochester

About Neuroendocrine Tumors Clinical Trials in Rochester

Neuroendocrine tumors (NETs) develop from hormone-producing cells and can occur in many organs, most commonly the gastrointestinal tract and lungs. They range from slow-growing to aggressive. Treatment includes surgery, somatostatin analogs, targeted therapy, and peptide receptor radionuclide therapy.

There are currently 3 neuroendocrine tumors clinical trials recruiting participants in Rochester, NY. These studies are seeking a combined 2,000,332 participants. Research is being sponsored by Helix, Inc, Perspective Therapeutics, Washington University School of Medicine. Clinical trial participation is free and participants receive study-related medical care at no cost.

Neuroendocrine Tumors Clinical Trials in Rochester — FAQ

Are there neuroendocrine tumors clinical trials in Rochester?

Yes, there are 3 neuroendocrine tumors clinical trials currently recruiting in Rochester, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Rochester?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Rochester research site will contact you about next steps.

Are clinical trials in Rochester free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Rochester studies also compensate for your time and travel.

What neuroendocrine tumors treatments are being tested?

The 3 active trials in Rochester are testing new therapies including novel drugs, biologics, and treatment approaches for neuroendocrine tumors.

Data updated July 13, 2026 from ClinicalTrials.gov